BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 38060328)

  • 1. PD-1H/VISTA mediates immune evasion in acute myeloid leukemia.
    Kim TK; Han X; Hu Q; Vandsemb EN; Fielder CM; Hong J; Kim KW; Mason EF; Plowman RS; Wang J; Wang Q; Zhang JP; Badri T; Sanmamed MF; Zheng L; Zhang T; Alawa J; Lee SW; Zeidan AM; Halene S; Pillai MM; Chandhok NS; Lu J; Xu ML; Gore SD; Chen L
    J Clin Invest; 2024 Feb; 134(3):. PubMed ID: 38060328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML.
    Wang L; Jia B; Claxton DF; Ehmann WC; Rybka WB; Mineishi S; Naik S; Khawaja MR; Sivik J; Han J; Hohl RJ; Zheng H
    Oncoimmunology; 2018; 7(9):e1469594. PubMed ID: 30228937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lactate acid promotes PD-1
    Zhang Y; Huang Y; Hong Y; Lin Z; Zha J; Zhu Y; Li Z; Wang C; Fang Z; Zhou Z; Peng Y; Yu X; Liu L; Xu B
    Int Immunopharmacol; 2024 Mar; 130():111765. PubMed ID: 38447414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapy.
    Knaus HA; Berglund S; Hackl H; Blackford AL; Zeidner JF; Montiel-Esparza R; Mukhopadhyay R; Vanura K; Blazar BR; Karp JE; Luznik L; Gojo I
    JCI Insight; 2018 Nov; 3(21):. PubMed ID: 30385732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia.
    Shen W; Patnaik MM; Ruiz A; Russell SJ; Peng KW
    Blood; 2016 Mar; 127(11):1449-58. PubMed ID: 26712908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triple combination targeting methyltransferase, BCL-2, and PD-1 facilitates antileukemia responses in acute myeloid leukemia.
    Zeng Z; Maiti A; Herbrich S; Cai T; Cavazos A; Manzella T; Ma H; Hayes K; Matthews J; DiNardo CD; Daver NG; Konopleva MY
    Cancer; 2023 Feb; 129(4):531-540. PubMed ID: 36477735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Combination of the Immunotherapeutic Drug Anti-Programmed Death 1 with Lenalidomide Enhances Specific T Cell Immune Responses against Acute Myeloid Leukemia Cells.
    Guinn BA; Schuler PJ; Schrezenmeier H; Hofmann S; Weiss J; Bulach C; Götz M; Greiner J
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Higher PD-1/Tim-3 expression on IFN-γ+ T cells is associated with poor prognosis in patients with acute myeloid leukemia.
    Huang S; Zhao Y; Lai W; Tan J; Zheng X; Zha X; Li Y; Chen S
    Cancer Biol Ther; 2023 Dec; 24(1):2278229. PubMed ID: 37962843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bifunctional PD-1 × αCD3 × αCD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia.
    Herrmann M; Krupka C; Deiser K; Brauchle B; Marcinek A; Ogrinc Wagner A; Rataj F; Mocikat R; Metzeler KH; Spiekermann K; Kobold S; Fenn NC; Hopfner KP; Subklewe M
    Blood; 2018 Dec; 132(23):2484-2494. PubMed ID: 30275109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BET bromodomain inhibition rescues PD-1-mediated T-cell exhaustion in acute myeloid leukemia.
    Zhong M; Gao R; Zhao R; Huang Y; Chen C; Li K; Yu X; Nie D; Chen Z; Liu X; Liu Z; Chen S; Lu Y; Yu Z; Wang L; Li P; Zeng C; Li Y
    Cell Death Dis; 2022 Aug; 13(8):671. PubMed ID: 35918330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia.
    Williams P; Basu S; Garcia-Manero G; Hourigan CS; Oetjen KA; Cortes JE; Ravandi F; Jabbour EJ; Al-Hamal Z; Konopleva M; Ning J; Xiao L; Hidalgo Lopez J; Kornblau SM; Andreeff M; Flores W; Bueso-Ramos C; Blando J; Galera P; Calvo KR; Al-Atrash G; Allison JP; Kantarjian HM; Sharma P; Daver NG
    Cancer; 2019 May; 125(9):1470-1481. PubMed ID: 30500073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of CD200 is a Stem Cell-Specific Mechanism of Immune Evasion in AML.
    Herbrich S; Baran N; Cai T; Weng C; Aitken MJL; Post SM; Henderson J; Shi C; Richard-Carpentier G; Sauvageau G; Baggerly K; Al-Atrash G; Davis RE; Daver N; Zha D; Konopleva M
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34326171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for AML.
    Masarova L; Kantarjian H; Garcia-Mannero G; Ravandi F; Sharma P; Daver N
    Adv Exp Med Biol; 2017; 995():73-95. PubMed ID: 28321813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ablation of T cell-associated PD-1H enhances functionality and promotes adoptive immunotherapy.
    Hu L; Chen L; Xiao Z; Zheng X; Chen Y; Xian N; Cho C; Luo L; Huang G; Chen L
    JCI Insight; 2022 Jan; 7(2):. PubMed ID: 34905507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia.
    Zhou Q; Munger ME; Highfill SL; Tolar J; Weigel BJ; Riddle M; Sharpe AH; Vallera DA; Azuma M; Levine BL; June CH; Murphy WJ; Munn DH; Blazar BR
    Blood; 2010 Oct; 116(14):2484-93. PubMed ID: 20570856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced Anti-Leukemic Effects through Induction of Immunomodulating Microenvironment by Blocking CXCR4 and PD-L1 in an AML Mouse Model.
    Hwang HS; Han AR; Lee JY; Park GS; Min WS; Kim HJ
    Immunol Invest; 2019 Jan; 48(1):96-105. PubMed ID: 30204524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD52 as a molecular target for immunotherapy to treat acute myeloid leukemia with high EVI1 expression.
    Saito Y; Nakahata S; Yamakawa N; Kaneda K; Ichihara E; Suekane A; Morishita K
    Leukemia; 2011 Jun; 25(6):921-31. PubMed ID: 21394097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coinhibitory receptor PD-1H preferentially suppresses CD4⁺ T cell-mediated immunity.
    Flies DB; Han X; Higuchi T; Zheng L; Sun J; Ye JJ; Chen L
    J Clin Invest; 2014 May; 124(5):1966-75. PubMed ID: 24743150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune-Based Therapeutic Interventions for Acute Myeloid Leukemia.
    Perna F; Espinoza-Gutarra MR; Bombaci G; Farag SS; Schwartz JE
    Cancer Treat Res; 2022; 183():225-254. PubMed ID: 35551662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased TOX expression concurrent with PD-1, Tim-3, and CD244 expression in T cells from patients with acute myeloid leukemia.
    Huang S; Liang C; Zhao Y; Deng T; Tan J; Zha X; Li Y; Chen S
    Cytometry B Clin Cytom; 2022 Mar; 102(2):143-152. PubMed ID: 34913594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.